Schultz-Machata A-M, Becke K, Weiss M
Universitätsklinik für Anästhesie, Allgemeine Intensivmedizin und Schmerztherapie, Klinische Abteilung für allgemeine Anästhesie und Intensivmedizin, Medizinische Universität Wien, 1090, Wien, Österreich,
Anaesthesist. 2014 Feb;63(2):135-43. doi: 10.1007/s00101-014-2293-z.
Efficient and safe pediatric perioperative pain therapy in the context of a multimodal pain therapy concept requires a slight to moderate opioid analgesic. Nalbuphine is a nearly ideal opioid for this purpose due to its unique pharmacological properties as a μ-receptor antagonist/κ-receptor agonist and a high safety profile. Nalbuphine is used clinically primarily in postoperative pain therapy administered as a bolus, continuous infusion and patient-controlled analgesia. Furthermore, it is administered in different regimens for pediatric diagnostic and interventional sedation.
在多模式疼痛治疗理念的背景下，高效且安全的儿科围手术期疼痛治疗需要使用轻度至中度的阿片类镇痛药。纳布啡因其作为μ受体拮抗剂/κ受体激动剂的独特药理特性和较高的安全性，几乎是用于此目的的理想阿片类药物。纳布啡在临床上主要用于术后疼痛治疗，给药方式包括静脉推注、持续输注和患者自控镇痛。此外，它还以不同的给药方案用于儿科诊断和介入性镇静。
